What it is
Vesugen is three amino acids in a row: lysine, glutamic acid, aspartic acid. PubChem holds the structure under the name Lys-Glu-Asp (CID 87571363), with the formula C15H26N4O8 and a molecular weight of 390.39. Searching PubChem for the word "vesugen" returns nothing; the trade name and the chemical record are not linked there (2026-11-13).
The sequence is confirmed by the originating group's own paper, which writes "vesugen (Lys-Glu-Asp)" (Khavinson et al. 2012, PMID 22808515). Add a proline and the chain becomes Prostamax, Lys-Glu-Asp-Pro, the series' prostate peptide. A different four-letter member, Cortagen (Ala-Glu-Asp-Pro), shares Prostamax's last three residues and is the series' brain-cortex peptide. It is the vessel entry in the same St Petersburg peptide bioregulator series, associated with V. Khavinson, that produced epitalon, the dipeptide Vilon and the brain-targeted tripeptide Pinealon. Vesugen is Vilon's two amino acids plus one more.
What the research shows
A PubMed search on 2026-11-13 for "vesugen" in titles and abstracts returned 6 records, published between 2008 and 2015. This entry read all six abstracts.
| Year | Kind of study | What the abstract reports | PMID |
|---|---|---|---|
| 2008 | Test-tube and cell models | With three related peptides: no direct antioxidant activity; limited lipid peroxidation; raised reactive oxygen species inside cells | 18546826 |
| 2008 | Low-oxygen (hypobaric hypoxia) model | Four peptides showed anti-hypoxic properties; pinealon "the most pronounced" | 18546825 |
| 2011 | Pineal tissue culture | Vesugen "had no effect on differentiation capacity" of immune cells but enhanced their proliferation | 22803057 |
| 2012 | Human prostate fibroblasts in culture | Raised two differentiation markers in aged cultures | 22808515 |
| 2014 | Blood-vessel lining cells in culture; computer model | Raised Ki-67, a marker of cell division; docking model of the peptide against the gene's promoter | 25051766 |
| 2015 | 32 patients aged 41–83 | "Significant anabolic effect" and slower ageing by biological-age indicators; also pro-oxidant activity and fewer CD34-positive cells | 26390612 |
Four of the six are in Russian, in the programme's own gerontology journal.
The one human report, read closely
The 2015 paper is the whole of the indexed human evidence. Its abstract describes 32 people with several chronic illnesses and a brain disorder in remission, given vesugen or pinealon.
Three things stand out. The abstract mentions no control group, no placebo and no randomisation. Its own head-count does not add up: "32 people (18 men, 12 women)" is 30. And its findings point both ways — alongside an "anabolic effect", the authors report pro-oxidant activity and a decrease in CD34-positive cells that they describe as "significant inhibition of hemopoiesis", meaning blood-cell formation. The abstract nonetheless ends by recommending the peptides for geriatric practice; that is the authors' recommendation, and this library reports it without endorsing it.
The 2014 cell paper refers to a "vasoprotective effect of peptide vesugen revealed previously in elder people." No PubMed record under the name contains that earlier study, and this entry could not find it.
What is not established
- A vessel benefit against a comparison group. The 32-patient report had none described, so its "slower ageing" reading cannot be separated from time, other treatment or chance.
- What the two warning signals mean. Pro-oxidant activity and fewer CD34-positive cells were reported in the same patients and then left there; no later indexed paper returns to them.
- The "earlier study in elder people". The 2014 paper cites a vasoprotective result in older people that no PubMed record under the name contains.
- Whether KED reaches the vessel wall. The endothelial-cell result came from peptide added straight to a culture dish; no abstract tracks it in blood.
- Work from a second group. No paper from outside the programme and its collaborators is indexed; four of the six appeared in its own journal.
Where it stands
- Regulatory status: unapproved in every record checked; PubChem knows the molecule only as Lys-Glu-Asp, not by the trade name.
- Where readers meet it: vessel and circulation bioregulator listings, alone or blended. Those products are not assessed here.
- Size of the record (2026-11-13): six PubMed papers from 2008 to 2015, one of them on people; ClinicalTrials.gov returns nothing for the name.
Related reading
The same programme's heart-labelled peptide is described in the cardiogen entry, and its cartilage-labelled one in the cartalax entry. The gland extract these short peptides descend from is covered under thymalin. For how the claims made for longevity peptides compare with their human evidence, see the longevity overview.
